Haifan Lin (Chinese: 林海帆; pinyin: Lín Hǎifān) is a Chinese-born American stem cell biologist.
He moved to the United States to pursue graduate studies at Cornell University and earned his PhD in 1990 in genetics and development.
[2] From 2014 to 2022, Lin served concurrently as the adjunct founding dean of ShanghaiTech University's School of Life Science and Technology in China, while retaining his positions at Yale.
[5] In recent years, he demonstrated the crucial roles of the Piwi-piRNA pathway in epigenetic programming and post-transcriptional regulation of mRNA and lncRNA (see Select Bibliography).
Lin has also served on the Medical Advisory Board of New York Stem Cell Foundation (2009–present), the US National Institutes of Health (NIH) Director's Pioneer Award Selection Committee (2009), the NIH study sections (1998-2005, 2007, 2012, 2014, 2019–2020), the Board of Directors of the Society of Chinese Biological Investigators, USA (2002-2008), the Council of the Society of Chinese Bioscientists in America (2008-2011), the Advisory Council of RIKEN Center for Developmental Biology, Japan (2007-2015), the Scientific Advisory Board of the Jane Coffin Childs Memorial Fund for Medical Research (2011-2015), National Key Stem Cell Research Advisory Committee, Chinese Ministry of Science and Technology (2011-2014), the Council of Shantou University (2010-2015), and the Council of Connecticut Academy of Science and Engineering (2013-2016).
Academic Awards: Elected Memberships: Lin was investigated by federal agencies under the Trump administration's China Initiative.